Anti-Synuclein-alpha/beta, 130-140 836601 from BioLegend | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
BioLegend for
Anti-Synuclein-alpha/beta, 130-140

The Anti-Synuclein-alpha/beta, 130-140 Antibody from BioLegend is a Mouse Monoclonal antibody to Snca, and Synuclein alpha. This antibody recognizes Homo Sapiens, Human, and Mouse antigen. The Anti-Synuclein-alpha/beta, 130-140 Antibody has been validated for the following applications: Electron Microscopy, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry - fixed, Immunoprecipitation, and Western Blot.

Description

Anti-Synuclein-alpha/beta, 130-140 [Syn 202]

Product Specs
ItemAnti-Synuclein-alpha/beta, 130-140
CompanyBioLegend
Price Pricing Info Supplier Page View Company Product Page
Catalog Number836601
Quantity200 µL
ApplicationsImmunohistochemistry (IHC)-P, Western Blot (WB), Electron Microscopy, Immunocytochemistry (ICC), Immunoprecipitation (IP)
Conjugate/TagUnconjugated
ReactivityHuman, Mouse
IsotypeIgG2a
CloneSyn 202
HostMouse
ImmunogenSyn 202 was raised using recombinant alpha and beta synucleins and recognizes residues 130-140 in alpha and beta synuclein
NCBI Full Gene Namesynuclein alpha
NCBI Gene AliasesNACP, PARK1, PARK4, PD1
ClonalityMonoclonal
Brand/TrademarkMMS-529R-200
TargetSynuclein-alpha/beta 130-140

Add to Compare List

BioLegend

BioLegend

8999 BioLegend Way

San Diego, California 92121

United States

Phone: 1-877-246-5343 Toll-Free, USA & Canada
1-858-768-5800 International
Fax: 1-877-455-9587

Company Profile

Website: biolegend.com

(1) Templated α-Synuclein Inclusion Formation Is Independent of Endogenous TaueNeuroMay 1, 2021Stoyka LE, Mahoney CL, Thrasher DR, Russell DL, Cook AK, Harris AT, Narayanan A, Janado TP, Standaert DG, Roberson ED, et al.

(2) The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's modelsCell metabolismJuly 1, 2014Knight AL, Yan X, Hamamichi S, Ajjuri RR, Mazzulli JR, Zhang MW, Daigle JG, Zhang S, Borom AR, Roberts LR, et al.

(3) Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicityThe Journal of neuroscience : the official journal of the Society for NeuroscienceMarch 21, 2012Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D.

(4) Activation of guanylate cyclase by streptozotocin and 1-methyl-1-nitrosoureaCancer researchJanuary 1, 1977D L Vesely, L E Rovere, G S Levey

Be the First to Write a Review!